



## SPHERUSOL Reimbursement FAQ

**Question:** *How do I get reimbursed for SPHERUSOL?*

**Answer:**

SPHERUSOL is a skin test antigen and therefore is reimbursed as part of the payment for the associated skin test, in this case, CPT code 86490 skin test; coccidioidomycosis. Medicare updated the payment rate for 86490 to reflect the cost of SPHERUSOL.

Charges for SPHERUSOL should be included in the charges reported for 86490, along with any other charges for items and services needed to perform the coccidioidomycosis skin test.

If you have any additional questions please contact Nielsen BioSciences, Inc. toll-free at 855.855.1212.or e-mail at [info@nielsenbio.com](mailto:info@nielsenbio.com)

**Please note that this information is provided only for informational purposes. Health care providers must make treatment and coding decisions based on their own independent medical judgment.**

### **SPHERUSOL (*Coccidioides Immitis*) Spherule-Derived Skin Test Antigen**

#### **INDICATION AND USAGE**

Spherusol is a skin test antigen indicated for the detection of delayed-type hypersensitivity to *Coccidioides immitis* in individuals with a history of pulmonary coccidioidomycosis. SPHERUSOL is approved for use in individuals 18-64 years of age. The use of SPHERUSOL to detect delayed-type hypersensitivity response in a general population with unknown exposure to *C. immitis* has not been evaluated. Persons with acute or disseminated coccidioidomycosis may not develop a delayed-type hypersensitivity response to SPHERUSOL. Persons with immunodeficiency and a history of coccidioidomycosis may not develop a delayed-type hypersensitivity response to SPHERUSOL.

**WARNING: The expected response to SPHERUSOL is a local area of inflammation at the site of the skin test. The reaction is usually dime to quarter size reaching maximum diameter between 24 and 48 hours. Larger accelerated reactions can occur, which may require treatment with local cold compresses and anti-inflammatory medication. Systemic reactions can occur with skin test antigens and in certain individuals these reactions may be life-threatening or cause death. Emergency measures and personnel trained in their use should be immediately available. Patients should be observed for at least 20 minutes following the administration of a skin test. SPHERUSOL should never be given intravenously.**

Please see **Important Safety Information** and **Full Prescribing Information** at [www.nielsenbio.com](http://www.nielsenbio.com)

\*CPT = Current Procedure Code; CPT®2014 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association.

©2017 Nielsen BioSciences, Inc. SPHERUSOL is a registered trademark of Nielsen BioSciences, Inc. All rights reserved.  
HCP009 10Apr2017